Business Milestones
2026.02.03
TAHO Pharmaceuticals to Present Scientific Abstract at APSC Congress 2026
TAHO Pharmaceuticals to Present Scientific Abstract at APSC Congress 2026
Taipei, Taiwan – February 3, 2026 – TAHO Pharmaceuticals Ltd. announced that the company will present a scientific poster at the Asian Pacific Society of Cardiology (APSC) Congress 2026, one of the leading cardiovascular conferences in the Asia-Pacific region. The poster presentation will take place during the congress on May 16, 2026, from 10:30 AM to 11:00 AM. The Asian Pacific Society of Cardiology (APSC) is a prominent regional organization dedicated to advancing cardiovascular medicine through scientific exchange, clinical research, and collaboration among cardiology professionals across the Asia-Pacific region. The annual APSC Congress brings together leading clinicians, researchers, and industry experts to share the latest developments in cardiovascular science and patient care. TAHO’s presentation will highlight its ongoing work related to TAH3311 and TAH3341, two programs about company’s innovative oral dissolving film drug delivery technology. By offering alternative dosage forms designed to improve ease of administration and patient adherence, these programs aim to address important challenges in cardiovascular therapy, particularly for patients who have difficulty swallowing conventional tablets. TAHO Pharmaceuticals continues to advance its pipeline of patient-friendly therapeutic solutions through its drug delivery technologies and looks forward to engaging with the global cardiovascular research community at APSC Congress 2026.
About TAHO Pharmaceuticals Ltd.
Founded in 2010, TAHO Pharma is a global small-to-medium enterprise (SME) specializing in innovative oral and transdermal drug delivery systems. Through its proprietary Transepithelial Delivery System (TDS) platform, TAHO enables efficient transdermal and transmucosal delivery of small-molecule drugs. The TDS platform provides significant advantages over conventional delivery routes, including tailored release profiles (from rapid onset to sustained delivery), reduced gastrointestinal side effects, enhanced bioavailability, and simplified administration for patients with compliance challenges. With TAHO’s scientifically differentiated technology and
clinically meaningful solutions, TAHO is dedicated to advancing patient care and improving quality of life worldwide.
Media Contact:
TAHO Pharmaceuticals
+886-2-2659-8515
[email protected]
Taipei, Taiwan – February 3, 2026 – TAHO Pharmaceuticals Ltd. announced that the company will present a scientific poster at the Asian Pacific Society of Cardiology (APSC) Congress 2026, one of the leading cardiovascular conferences in the Asia-Pacific region. The poster presentation will take place during the congress on May 16, 2026, from 10:30 AM to 11:00 AM. The Asian Pacific Society of Cardiology (APSC) is a prominent regional organization dedicated to advancing cardiovascular medicine through scientific exchange, clinical research, and collaboration among cardiology professionals across the Asia-Pacific region. The annual APSC Congress brings together leading clinicians, researchers, and industry experts to share the latest developments in cardiovascular science and patient care. TAHO’s presentation will highlight its ongoing work related to TAH3311 and TAH3341, two programs about company’s innovative oral dissolving film drug delivery technology. By offering alternative dosage forms designed to improve ease of administration and patient adherence, these programs aim to address important challenges in cardiovascular therapy, particularly for patients who have difficulty swallowing conventional tablets. TAHO Pharmaceuticals continues to advance its pipeline of patient-friendly therapeutic solutions through its drug delivery technologies and looks forward to engaging with the global cardiovascular research community at APSC Congress 2026.
About TAHO Pharmaceuticals Ltd.
Founded in 2010, TAHO Pharma is a global small-to-medium enterprise (SME) specializing in innovative oral and transdermal drug delivery systems. Through its proprietary Transepithelial Delivery System (TDS) platform, TAHO enables efficient transdermal and transmucosal delivery of small-molecule drugs. The TDS platform provides significant advantages over conventional delivery routes, including tailored release profiles (from rapid onset to sustained delivery), reduced gastrointestinal side effects, enhanced bioavailability, and simplified administration for patients with compliance challenges. With TAHO’s scientifically differentiated technology and
clinically meaningful solutions, TAHO is dedicated to advancing patient care and improving quality of life worldwide.
Media Contact:
TAHO Pharmaceuticals
+886-2-2659-8515
[email protected]